2633-42-3

Basic information

• Product Name: Ethanone, 2-bromo-1-(2,6-dimethylphenyl)-
• CAS NO: 2633-42-3
• Molecular Formula: C10H11BrO
• Molecular Weight: 227.101
• Mol File: 2633-42-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Ethanone, 2-bromo-1-(2,6-dimethylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-(2,6-dimethylphenyl)-(2633-42-3)
• EPA Substance Registry System: Ethanone, 2-bromo-1-(2,6-dimethylphenyl)-(2633-42-3)

Safety Data

• Hazardous Substances Data: 2633-42-3(Hazardous Substances Data)

Usage

General Description

Ethanone, 2-bromo-1-(2,6-dimethylphenyl)- is a chemical compound with the formula C10H11BrO. It is a brominated derivative of acetophenone and consists of a bromine atom and a 2,6-dimethylphenyl group attached to the carbon atom of the carbonyl group. Ethanone, 2-bromo-1-(2,6-dimethylphenyl)- is used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also utilized in research and development for its unique chemical properties and reactivity. Additionally, it is important to handle and store this compound with care due to its potential hazards.

Upstream product

• 576-22-7 2-Bromo-m-xylene 
• 2142-76-9 2',6'-dimethylacetophenone 
• 82204-76-0 1-(2,6-dimethylphenyl)ethanimine 
• 6575-13-9 2,6-dimethylbenzonitrile 

Downstream Products

• 1415838-58-2 8-(butylamino)-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione 
• 1415838-69-5 C₂₀H₂₃N₅O₂ 
• 1415838-47-9 8-bromo-7-(2-(2,6-dimethylphenyl)-2-oxoethyl)-3-methyl-1H-purine-2,6(3H,7H)-dione 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography

Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors. We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent molecular dynamics simulations. Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compound. In addition, respectable levels of antiproliferative activity for these compounds have been obtained. Finally, the binding mode predicted by docking and molecular dynamics simulations is validated by solving the crystal structures of three members of this chemical class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.

Alkenyl bromides by brominative deoxygenation of ketones in one or two steps

The conversion of ketones into alkenyl bromides is accomplished in one or two steps by 2,2,2-tribromo-2,2-dihydro-1,3,2-benzodioxaphosphole or by the dibromomethyl methyl ether prepared therefrom. Investigations of the scope and limitations provide some hints for the preparative planning and improvement.